NCT05252416 2025-11-28
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase 1 Terminated
Blueprint Medicines Corporation
Bio-Thera Solutions
University of Maryland, Baltimore
Ohio State University Comprehensive Cancer Center